Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Equivalents (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Cash & Equivalents data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 256.6% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 256.6%, while the annual FY2025 figure was $1.3 million, 256.6% up from the prior year.
  • Cash & Equivalents reached $1.3 million in Q4 2025 per TGTX's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $471.5 million in Q1 2021 and bottomed at $371000.0 in Q4 2024.
  • Average Cash & Equivalents over 5 years is $146.8 million, with a median of $106.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 805.87% in 2021, then plummeted 99.6% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $298.9 million in 2021, then plummeted by 65.77% to $102.3 million in 2022, then fell by 9.16% to $92.9 million in 2023, then tumbled by 99.6% to $371000.0 in 2024, then soared by 256.6% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.3 million in Q4 2025, $1.8 million in Q3 2025, and $1.3 million in Q2 2025.